dc.creator | Brys, Ivani | |
dc.creator | Bobela, Wojciech | |
dc.creator | Schneider, Bernard L. | |
dc.creator | Aebischer, Patrick | |
dc.creator | Fuentes, Romulo | |
dc.date.accessioned | 2019-03-18T11:53:46Z | |
dc.date.available | 2019-03-18T11:53:46Z | |
dc.date.created | 2019-03-18T11:53:46Z | |
dc.date.issued | 2017 | |
dc.identifier | International Journal of Neuroscience, Volumen 127, Issue 1, 2018, Pages 28-36 | |
dc.identifier | 15635279 | |
dc.identifier | 00207454 | |
dc.identifier | 10.3109/00207454.2016.1138296 | |
dc.identifier | https://repositorio.uchile.cl/handle/2250/166725 | |
dc.description.abstract | Copyright © 2016 Informa UK Limited, trading as Taylor & Francis Group.Neuromodulation by spinal cord stimulation has been proposed as a symptomatic treatment for Parkinson’s disease. We tested the chronic effects of spinal cord stimulation in a progressive model of Parkinson’s based on overexpression of alpha-synuclein in the substantia nigra. Adult Sprague Dawley rats received unilateral injections of adeno-associated virus serotype 6 (AAV6) in the substantia nigra to express alpha-synuclein. Locomotion and forepaw use of the rats were evaluated during the next 10 weeks. Starting on week 6, a group of AAV6-injected rats received spinal cord stimulation once a week. At the end of the experiment, tyrosine hydroxylase and alpha-synuclein immunostaining were performed. Rats with unilateral alpha-synuclein expression showed a significant decrease in the use of the contralateral forepaw, which was mildly but significantly reverted by spinal cord stimulation applied once a week from the 6th | |
dc.language | en | |
dc.publisher | Taylor and Francis Ltd | |
dc.rights | http://creativecommons.org/licenses/by-nc-nd/3.0/cl/ | |
dc.rights | Attribution-NonCommercial-NoDerivs 3.0 Chile | |
dc.source | International Journal of Neuroscience | |
dc.subject | alpha-synuclein | |
dc.subject | Parkinson’s disease | |
dc.subject | spinal cord stimulation | |
dc.title | Spinal cord stimulation improves forelimb use in an alpha-synuclein animal model of Parkinson’s disease | |
dc.type | Artículo de revista | |